Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro
Tóm tắt
The horse is a valuable species to assess the effect of allogeneic mesenchymal stromal cells (MSCs) in regenerative treatments. No studies to date have examined recipient response to major histocompatibility complex (MHC)-mismatched equine MSCs. The purposes of this study were to immunophenotype MSCs from horses of known MHC haplotype and to compare the immunogenicity of MSCs with differing MHC class II expression. MSCs and peripheral blood leukocytes (PBLs) were obtained from Thoroughbred horses (n = 10) of known MHC haplotype (ELA-A2, -A3, and -A9 homozygotes). MSCs were cultured through P8; cells from each passage (P2 to P8) were cryopreserved until used. Immunophenotyping of MHC class I and II, CD44, CD29, CD90, LFA-1, and CD45RB was performed by using flow cytometry. Tri-lineage differentiation assays were performed to confirm MSC multipotency. Recombinant equine IFN-γ was used to stimulate MHC class II negative MSCs in culture, after which expression of MHC class II was re-examined. To assess the ability of MHC class II negative or positive MSCs to stimulate an immune response, modified one-way mixed leukocyte reactions (MLRs) were performed by using MHC-matched and mismatched responder PBLs and stimulator PBLs or MSCs. Proliferation of gated CFSE-labeled CD3+ responder T cells was evaluated via CFSE attenuation by using flow cytometry and reported as the number of cells in the proliferating T-cell gate. MSCs varied widely in MHC class II expression despite being homogenous in terms of “stemness” marker expression and ability to undergo trilineage differentiation. Stimulation of MHC class II negative MSCs with IFN-γ resulted in markedly increased expression of MHC class II. MLR results revealed that MHC-mismatched MHC class II-positive MSCs caused significantly increased responder T-cell proliferation compared with MHC-mismatched MHC class II-negative and MHC-matched MSCs, and equivalent to that of the positive control of MHC-mismatched leukocytes. The results of this study suggest that MSCs should be confirmed as MHC class II negative before allogeneic application. Additionally, it must be considered that even MHC class II-negative MSCs could upregulate MHC class II expression if implanted into an area of active inflammation, as demonstrated with in vitro stimulation with IFN-γ.
Tài liệu tham khảo
Griffin MD, Ryan AE, Alagesan S, Lohan P, Treacy O, Ritter T: Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far?. Immunol Cell Biol. 2013, 91: 40-51. 10.1038/icb.2012.67.
Stagg J, Galipeau J: Immune plasticity of bone marrow-derived mesenchymal stromal cells. Handb Exp Pharmacol. 2007, 180: 45-66. 10.1007/978-3-540-68976-8_3.
Stagg J: Immune regulation by mesenchymal stem cells: two sides to the coin. Tissue Antigens. 2007, 69: 1-9.
Griffin MD, Ritter T, Mahon BP: Immunological aspects of allogeneic mesenchymal stem cell therapies. Hum Gene Ther. 2010, 21: 1641-1655. 10.1089/hum.2010.156.
Eliopoulos N, Stagg J, Lejeune L, Pommey S, Galipeau J: Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood. 2005, 106: 4057-4065. 10.1182/blood-2005-03-1004.
Potian JA, Aviv H, Ponzio NM, Harrison JS, Rameshwar P: Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol. 2003, 171: 3426-3434.
Zangi L, Margalit R, Reich-Zeliger S, Bachar-Lustig E, Beilhack A, Negrin R, Reisner Y: Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells. Stem Cells. 2009, 27: 2865-2874. 10.1002/stem.217.
Badillo AT, Beggs KJ, Javazon EH, Tebbets JC, Flake AW: Murine bone marrow stromal progenitor cells elicit an in vivo cellular and humoral alloimmune response. Biol Blood Marrow Transplant. 2007, 13: 412-422. 10.1016/j.bbmt.2006.12.447.
Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE: Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood. 2006, 108: 2114-2120. 10.1182/blood-2005-11-011650.
Jones EA, Kinsey SE, English A, Jones RA, Straszynski L, Meredith DM, Markham AF, Jack A, Emery P, McGonagle D: Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. Arthritis Rheum. 2002, 46: 3349-3360. 10.1002/art.10696.
Fortier LA: Making progress in the what, when and where of regenerative medicine for our equine patients. Equine Vet J. 2012, 44: 511-512. 10.1111/j.2042-3306.2012.00628.x.
Fortier LA, Travis AJ: Stem cells in veterinary medicine. Stem Cell Res Ther. 2011, 2: 9-14. 10.1186/scrt50.
Frisbie DD, Smith RK: Clinical update on the use of mesenchymal stem cells in equine orthopaedics. Equine Vet J. 2010, 42: 86-89.
Frisbie DD, Stewart MC: Cell-based therapies for equine joint disease. Vet Clin North Am Equine Pract. 2011, 27: 335-349. 10.1016/j.cveq.2011.06.005.
Schnabel LV, Fortier LA, McIlwraith CW, Nobert KM: Therapeutic use of stem cells in horses: which type, how, and when?. Vet J. 2013, 197: 570-577. 10.1016/j.tvjl.2013.04.018.
De Schauwer C, Van de Walle GR, Van Soom A, Meyer E: Mesenchymal stem cell therapy in horses: useful beyond orthopedic injuries?. Vet Q. 2013, epub ahead of print
Guest DJ, Ousey JC, Smith MRW: Defining the expression of marker genes in equine mesenchymal stromal cells. Stem Cell Cloning Adv Appl. 2008, 1: 1-9.
De Schauwer C, Meyer E, Van de Walle GR, Van Soom A: Markers of stemness in equine mesenchymal stem cells: a plea for uniformity. Theriogenology. 2011, 75: 1431-1443. 10.1016/j.theriogenology.2010.11.008.
Carrade DD, Lame MW, Kent MS, Clark KC, Walker NJ, Borjesson DL: Comparative analysis of the immunomodulatory properties of equine adult-derived mesenchymal stem cells. Cell Med. 2012, 4: 1-11. 10.3727/215517912X647217.
Guest DJ, Smith MR, Allen WR: Monitoring the fate of autologous and allogeneic mesenchymal progenitor cells injected into the superficial digital flexor tendon of horses: preliminary study. Equine Vet J. 2008, 40: 178-181. 10.2746/042516408X276942.
Schnabel LV, Lynch ME, van der Meulen MC, Yeager AE, Kornatowski MA, Nixon AJ: Mesenchymal stem cells and insulin-like growth factor-I gene-enhanced mesenchymal stem cells improve structural aspects of healing in equine flexor digitorum superficialis tendons. J Orthop Res. 2009, 27: 1392-1398. 10.1002/jor.20887.
Godwin EE, Young NJ, Dudhia J, Beamish IC, Smith RK: Implantation of bone marrow-derived mesenchymal stem cells demonstrates improved outcome in horses with overstrain injury of the superficial digital flexor tendon. Equine Vet J. 2012, 44: 25-32. 10.1111/j.2042-3306.2011.00363.x.
Wilke MM, Nydam DV, Nixon AJ: Enhanced early chondrogenesis in articular defects following arthroscopic mesenchymal stem cell implantation in an equine model. J Orthop Res. 2007, 25: 913-925. 10.1002/jor.20382.
Ferris DJ, Frisbie DD, Kisiday JD, McIlwraith CW, Hague BA, Major MD, Schneider RK, Zubrod CJ, Kawcak CE, Goodrich LR: Vet Surg. 2014, In press
Frisbie DD, Kisiday JD, Kawcak CE, Werpy NM, McIlwraith CW: Evaluation of adipose-derived stromal vascular fraction or bone marrow-derived mesenchymal stem cells for treatment of osteoarthritis. J Orthop Res. 2009, 27: 1675-1680. 10.1002/jor.20933.
McIlwraith CW, Frisbie DD, Rodkey WG, Kisiday JD, Werpy NM, Kawcak CE, Steadman JR: Evaluation of intra-articular mesenchymal stem cells to augment healing of microfractured chondral defects. Arthroscopy. 2011, 27: 1552-1561. 10.1016/j.arthro.2011.06.002.
Lazary S, Antczak DF, Bailey E, Bell TK, Bernoco D, Byrns G, McClure JJ: Joint Report of the Fifth International Workshop on Lymphocyte Alloantigens of the Horse; Baton Rouge, Louisiana, 31 October to 1 November 1987. Anim Genet. 1988, 19: 447-456.
Tallmadge RL, Campbell JA, Miller DC, Antczak DF: Analysis of MHC class I genes across horse MHC haplotypes. Immunogenetics. 2010, 62: 159-172. 10.1007/s00251-009-0420-9.
Tallmadge RL, Lear TL, Antczak DF: Genomic characterization of MHC class I genes of the horse. Immunogenetics. 2005, 57: 763-774. 10.1007/s00251-005-0034-9.
Tseng CT, Miller D, Cassano J, Bailey E, Antczak DF: Identification of equine major histocompatibility complex haplotypes using polymorphic microsatellites. Anim Genet. 2010, 41: 150-153.
Flaminio MJ, Antczak DF: Inhibition of lymphocyte proliferation and activation: a mechanism used by equine invasive trophoblast to escape the maternal immune response. Placenta. 2005, 26: 148-159. 10.1016/j.placenta.2004.05.008.
Radcliffe CH, Flaminio MJ, Fortier LA: Temporal analysis of equine bone marrow aspirate during establishment of putative mesenchymal progenitor cell populations. Stem Cells Dev. 2010, 19: 269-282. 10.1089/scd.2009.0091.
Watts AE, Ackerman-Yost JC, Nixon AJ: A comparison of three-dimensional culture systems to evaluate in vitro chondrogenesis of equine bone marrow-derived mesenchymal stem cells. Tissue Eng Part A. 2013, 19: 2275-2283. 10.1089/ten.tea.2012.0479.
Chan WK, Lau AS, Li JC, Law HK, Lau YL, Chan GC: MHC expression kinetics and immunogenicity of mesenchymal stromal cells after short-term IFN-gamma challenge. Exp Hematol. 2008, 36: 1545-1555. 10.1016/j.exphem.2008.06.008.
Romieu-Mourez R, Francois M, Boivin MN, Stagg J, Galipeau J: Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density. J Immunol. 2007, 179: 1549-1558.
Crovace A, Lacitignola L, De Siena R, Rossi G, Francioso E: Cell therapy for tendon repair in horses: an experimental study. Vet Res Commun. 2007, 31: 281-283. 10.1007/s11259-007-0047-y.
Crovace A, Lacitignola L, Rossi G, Francioso E: Histological and immunohistochemical evaluation of autologous cultured bone marrow mesenchymal stem cells and bone marrow mononucleated cells in collagenase-induced tendinitis of equine superficial digital flexor tendon. Vet Med Int. 2010, 2010: 250978-
Antczak DF, Bailey E, Barger B, Guerin G, Lazary S, McClure J, Mottironi VD, Symons R, Templeton J, Varewyck H: Joint report of the Third International Workshop on Lymphocyte Alloantigens of the Horse, Kennett Square, Pennsylvania, 25–27 April 1984. Anim Genet. 1986, 17: 363-373.
Delling U, Lindner K, Ribitsch I, Julke H, Brehm W: Comparison of bone marrow aspiration at the sternum and the tuber coxae in middle-aged horses. Can J Vet Res. 2012, 76: 52-56.
Baxter MA, Wynn RF, Jowitt SN, Wraith JE, Fairbairn LJ, Bellantuono I: Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells. 2004, 22: 675-682. 10.1634/stemcells.22-5-675.
Majors AK, Boehm CA, Nitto H, Midura RJ, Muschler GF: Characterization of human bone marrow stromal cells with respect to osteoblastic differentiation. J Orthop Res. 1997, 15: 546-557. 10.1002/jor.1100150410.